文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

日本结直肠癌学会(JSCCR)2019 年结直肠癌治疗指南。

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.

机构信息

Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8606, Japan.

Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

出版信息

Int J Clin Oncol. 2020 Jan;25(1):1-42. doi: 10.1007/s10147-019-01485-z. Epub 2019 Jun 15.


DOI:10.1007/s10147-019-01485-z
PMID:31203527
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6946738/
Abstract

The number of deaths from colorectal cancer in Japan continues to increase. Colorectal cancer deaths exceeded 50,000 in 2016. In the 2019 edition, revision of all aspects of treatments was performed, with corrections and additions made based on knowledge acquired since the 2016 version (drug therapy) and the 2014 version (other treatments). The Japanese Society for Cancer of the Colon and Rectum guidelines 2019 for the treatment of colorectal cancer (JSCCR guidelines 2019) have been prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment and to deepen mutual understanding between healthcare professionals and patients by making these guidelines available to the general public. These guidelines have been prepared by consensuses reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. Controversial issues were selected as clinical questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSCCR guidelines 2019.

摘要

日本结直肠癌死亡人数持续增加。2016 年,结直肠癌死亡人数超过 5 万。在 2019 年版中,对治疗的各个方面进行了修订,根据自 2016 年版(药物治疗)和 2014 年版(其他治疗)以来获得的知识进行了修正和补充。为了展示结直肠癌的标准治疗策略,消除机构之间在治疗方面的差异,消除不必要的和不足的治疗,并通过向公众提供这些指南来加深医疗保健专业人员和患者之间的相互理解,制定了 2019 年日本结直肠癌协会(JSCCR)结直肠癌治疗指南(JSCCR 指南 2019)。这些指南是由 JSCCR 指南委员会在仔细审查通过文献检索检索到的证据的基础上达成共识制定的,同时考虑到日本的医疗保险制度和实际临床实践环境。因此,这些指南可以作为实际临床实践中治疗结直肠癌的工具。更具体地说,它们可以作为从患者那里获得知情同意并为每位患者选择治疗方法的指南。选择了有争议的问题作为临床问题,并提出了建议。每个建议都附有证据的分类和根据指南委员会成员达成的共识的推荐类别分类。在这里,我们呈现了 2019 年 JSCCR 指南的英文版。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/9c9cdcff35ae/10147_2019_1485_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/e3cc69f0e023/10147_2019_1485_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/6c3c40052b52/10147_2019_1485_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/d143a3ef4b96/10147_2019_1485_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/e8abc3272e83/10147_2019_1485_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/f95f6c24114a/10147_2019_1485_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/3b01227ba2cd/10147_2019_1485_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/bea109e7f89e/10147_2019_1485_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/fbc0d29c9b82/10147_2019_1485_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/b3bbafaf2b7d/10147_2019_1485_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/f0b017afea83/10147_2019_1485_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/9c9cdcff35ae/10147_2019_1485_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/e3cc69f0e023/10147_2019_1485_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/6c3c40052b52/10147_2019_1485_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/d143a3ef4b96/10147_2019_1485_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/e8abc3272e83/10147_2019_1485_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/f95f6c24114a/10147_2019_1485_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/3b01227ba2cd/10147_2019_1485_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/bea109e7f89e/10147_2019_1485_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/fbc0d29c9b82/10147_2019_1485_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/b3bbafaf2b7d/10147_2019_1485_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/f0b017afea83/10147_2019_1485_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f28/6946738/9c9cdcff35ae/10147_2019_1485_Fig11_HTML.jpg

相似文献

[1]
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.

Int J Clin Oncol. 2019-6-15

[2]
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

Int J Clin Oncol. 2011-10-15

[3]
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.

Int J Clin Oncol. 2018-2

[4]
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer.

Int J Clin Oncol. 2015-4

[5]
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version).

J Anus Rectum Colon. 2018-5-25

[6]
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer.

Int J Clin Oncol. 2021-8

[7]
Impact of revisions of the JSCCR guidelines on the treatment of T1 colorectal carcinomas in Japan.

Z Gastroenterol. 2015-4

[8]
[Essential and interpretation of Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer].

Zhonghua Wei Chang Wai Ke Za Zhi. 2019-11-25

[9]
Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer.

Int J Clin Oncol. 2018-10-5

[10]
Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment.

J Gynecol Oncol. 2024-1

引用本文的文献

[1]
Surgical strategy for repeated metastasectomy for advanced colorectal cancer with synchronous liver metastases.

Surg Today. 2025-9-9

[2]
Development of a predictive score for prolonged pelvic operation time in robot-assisted low anterior resection: a single-center, retrospective study in Japan.

Surg Endosc. 2025-9-8

[3]
Partial resection of rectum for rectal GIST by posterior approach.

Langenbecks Arch Surg. 2025-8-29

[4]
Evidence for imaging-based diagnosis of liver metastases from colorectal cancer.

J Gastroenterol. 2025-8-22

[5]
Does Omitting Additional Surgery After Local Resection Affect Oncological Outcomes in Patients with High-Risk pT1 Colorectal Cancer?

J Gastrointest Cancer. 2025-8-20

[6]
Three-dimensional (3D) vascular reconstruction of the superior mesenteric vessels: a practical tool for the young surgeon approaching right hemicolectomy with CME technique.

BMC Surg. 2025-8-20

[7]
Quantitative Evaluation of the Invasion Depth of Colorectal Cancer Located on a Colorectal Fold Through the Width of Colorectal-Fold Lateral Contour Using a Lateral Split-View Computed Tomographic Air-Contrast Enema Image.

Cureus. 2025-7-14

[8]
CT diagnostic performance for preoperative staging of colon cancer: a systematic review and meta-analysis.

Eur Radiol. 2025-8-6

[9]
Tumor Budding as a Risk Factor for Lymph Node Metastasis and Local Recurrence in pT1 Colorectal Cancer: A Systematic Review and Meta-Analysis.

Gastro Hep Adv. 2025-5-27

[10]
Establishment of Coala: a novel 3D and 2D cancer cell line derived from colorectal cancer liver metastasis.

Hum Cell. 2025-8-4

本文引用的文献

[1]
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version).

J Anus Rectum Colon. 2018-5-25

[2]
Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma: the 3d English Edition [Secondary Publication].

J Anus Rectum Colon. 2019-10-30

[3]
Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition.

Cancer Sci. 2018-6

[4]
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer.

ESMO Open. 2018-4-24

[5]
A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.

Eur J Cancer. 2018-4-17

[6]
Validation study for development of the Japan NBI Expert Team classification of colorectal lesions.

Dig Endosc. 2018-6-26

[7]
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

N Engl J Med. 2018-3-29

[8]
Prognostic Impact of R0 Resection and Targeted Therapy for Colorectal Cancer with Synchronous Peritoneal Metastasis.

Ann Surg Oncol. 2018-3-23

[9]
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.

Lancet Oncol. 2018-3-16

[10]
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.

Clin Colorectal Cancer. 2018-2-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索